First-line bevacizumab treatment cost-effective for CRVO or HRVO-associated macular oedema: JAMA Medha Baranwal23 May 2023 10:30 AM ISTUSA: First-line treatment with bevacizumab of macular oedema associated with central or hemiretinal vein occlusion was cost-effective in a new...
Trifluridine-tipiracil and bevacizumab improve survival in colorectal cancer: NEJM Jacinthlyn Sylvia8 May 2023 8:00 PM ISTA new study by Gerald Prager and team showed that treatment with trifluridine-tipiracil (FTD-TPI) with bevacizumab led to a longer overall survival in...
Biocon Biologics Bengaluru facility gets EU GMP certification for Bevacizumab Ruchika Sharma29 April 2023 11:47 AM ISTBangalore: Biocon Biologics’ integrated, multi-product, monoclonal antibodies (mAbs) Drug Substance manufacturing facility (B3) at Biocon Park,...
AstraZeneca announces positive results from ovarian cancer combo therapy trial Ruchika Sharma7 April 2023 11:30 AM ISTThe safety and tolerability of these combinations are broadly consistent with that observed in prior clinical trials and the known profiles of the...
Late-line treatment with Bevacizumab alone or in combination with Chemotherapy beneficial in Recurrent High-Grade Glioma Dr. Krishna Shah3 April 2023 9:45 AM ISTBevacizumab alone or in combination with chemotherapy could be beneficial as a late-line therapy in a subset of patients with recurrent high-grade...
Bevacizumab substantially cost effective compared with aflibercept monotherapy for diabetic macular edema: JAMA Dr Ishan Kataria10 March 2023 8:00 PM ISTIntravitreous anti-vascular endothelial growth factor (VEGF) injections are the standard treatment for eyes with vision loss from diabetic macular...
Biocon partner Viatris gets Complete Response Letter from USFDA for Bevacizumab license application Ruchika Sharma13 Feb 2023 11:13 AM ISTBevacizumab is a medication used to treat a number of types of cancers and a specific eye disease.
Postnatal Growth Trajectories Outcomes shows no differences Following Bevacizumab Treatment for ROP Dr Ishan Kataria31 Oct 2022 8:45 PM ISTRetinopathy of prematurity (ROP) is a leading cause of childhood blindness characterized by neovascularization of the immature retina that can...
AstraZeneca, Merck get Chinese nod for Lynparza to treat ovarian cancer Ruchika Sharma24 Sept 2022 3:24 PM ISTIn China, Lynparza is approved for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer as well as a 1st-line maintenance...
AstraZeneca Lynparza shows clinically meaningful survival benefit in 1st-line advanced ovarian cancer across two Phase III trials Ruchika Sharma11 Sept 2022 1:15 PM ISTOvarian cancer is one of the most common gynaecologic cancers, with a poor prognosis and a high mortality rate.
Biocon arm gets multiple USFDA observations across India, Malaysia Ruchika Sharma1 Sept 2022 5:00 PM ISTBiocon said the inspections were on account of three pre-approval inspections for biosimilar Bevacizumab, rh-Insulin and Insulin Aspart and a capacity...
Biocon Biologics, Viatris launch cancer medicine Abevmy in Canada Ruchika Sharma20 May 2022 3:02 PM ISTAbevmy is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor (VEGF) and neutralizes its...
